Literature DB >> 16630526

Primary hormone therapy for locally advanced prostate cancer.

Gregory P Swanson1.   

Abstract

Locally advanced prostate cancer is a treatment dilemma. As with prostate cancer in general, there is no clear evidence that aggressive intervention (ie, surgery or radiation) is superior to noninvasive interventions (eg, delayed treatment or androgen ablation). Because patients with locally advanced prostate cancer have a high risk of local and systemic recurrence, there is some argument to proceed with androgen ablation as the sole modality of treatment. The data using this approach are limited, but an understanding of the degree and duration of response is helpful in selecting patients for primary androgen ablation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630526     DOI: 10.1007/s11934-006-0025-x

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  37 in total

1.  Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma.

Authors:  A Dupont; L Cusan; J L Gomez; M Koutsilieris; R Suburu; J Emond; F Labrie
Journal:  Br J Urol       Date:  1993-11

2.  Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies.

Authors:  J L EMMETT; L F GREENE; A PAPANTONIOU
Journal:  J Urol       Date:  1960-04       Impact factor: 7.450

3.  Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases.

Authors:  R M NESBIT; W C BAUM
Journal:  J Am Med Assoc       Date:  1950-08-12

4.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

Authors: 
Journal:  Br J Urol       Date:  1997-02

5.  Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.

Authors:  M E Gleave; S L Goldenberg; J L Chin; J Warner; F Saad; L H Klotz; M Jewett; V Kassabian; M Chetner; C Dupont; S Van Rensselaer
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

6.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Authors:  M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

7.  Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.

Authors:  P C Sogani; M R Vagaiwala; W F Whitmore
Journal:  Cancer       Date:  1984-08-15       Impact factor: 6.860

Review 8.  The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.

Authors:  F J Mayer; E D Crawford
Journal:  Urol Clin North Am       Date:  1994-11       Impact factor: 2.241

9.  Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer.

Authors:  Juan Morote; Enrique Trilla; Salvador Esquena; José María Abascal; Jaume Reventos
Journal:  Int J Cancer       Date:  2004-03-01       Impact factor: 7.396

10.  High-dose bicalutamide monotherapy for the treatment of prostate cancer.

Authors:  G R Blackledge
Journal:  Urology       Date:  1996-01       Impact factor: 2.649

View more
  1 in total

1.  PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.

Authors:  Elana Godebu; Michelle Muldong; Amy Strasner; Christina N Wu; Seung Chol Park; Jason R Woo; Wenxue Ma; Michael A Liss; Takeshi Hirata; Omer Raheem; Nicholas A Cacalano; Anna A Kulidjian; Christina A M Jamieson
Journal:  J Transl Med       Date:  2014-10-03       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.